Healthcare / Drug Manufacturers - Specialty & GenericShenzhen
$29.05
-0.28 (-0.95%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $41.5M · quality 69.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
43/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$3.1B
P/E
35.0x
↑EV/EBITDA
13.8x
↑ROE
5.7%
↑Gross Margin
51.9%
↑Debt/Equity
0.06
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+5.4%
FCF CAGR
-33.3%
FCF margin
1.8%
FCF / Net income
0.21x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.14B · net income $96.3M · FCF $20.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.14B | $1.14B | $973.9M | $980.8M | $974.3M |
| Net Income | $96.3M | $96.3M | $120.3M | $110.4M | $101.2M |
| EBITDA | $148.0M | $148.0M | $171.5M | $166.4M | $151.4M |
| EPS | 0.92 | 0.92 | 1.15 | 1.13 | 1.17 |
| Gross Margin | 51.9% | 51.9% | 60.8% | 57.9% | 58.1% |
| Operating Margin | 10.7% | 10.7% | 12.0% | 12.8% | 12.8% |
| Net Margin | 8.4% | 8.4% | 12.3% | 11.3% | 10.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.06 | 0.06 | 0.09 | 0.07 | 0.42 |
| Current Ratio | 3.76 | 3.76 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $20.6M | $20.6M | $74.5M | $41.5M | $69.5M |
| Returns | |||||
| ROE | 5.7% | 5.7% | 7.4% | 7.1% | 10.9% |
| Valuation | |||||
| P/E | 35.00 | 35.00 | 26.86 | 33.87 | 31.67 |
| EV/EBITDA | 13.83 | 13.83 | 12.91 | 16.47 | 18.32 |
| P/B | 1.80 | 1.80 | 1.98 | 2.41 | 3.45 |
| Growth & Yield | |||||
| Revenue Growth | 17.1% | 17.1% | -0.7% | 0.7% | — |
| EPS Growth | -20.0% | -20.0% | 1.8% | -3.4% | — |
| Dividend Yield | 1.2% | 1.2% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
41.0%
EPS terminal req.
$2.58
Spread vs growth
-61.0%
5Y implied EPS CAGR
27.7%
EPS terminal req.
$3.12
Spread vs growth
-47.7%
10Y implied EPS CAGR
18.5%
EPS terminal req.
$5.02
Spread vs growth
-38.5%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+3.8%
Start / end P/E
24.6x → 31.6x
EPS bridge
1.15 → 0.92
Residual
-5.7%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.